Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark's Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat® Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254].

According to IQVIA® sales data for the 12-month period ending April 2026, the Vimpat® Injection market achieved annual sales of approximately $15.2 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2165.50 as compared to the previous close of Rs. 2181.45. The total number of shares traded during the day was 45631 in over 3030 trades.

The stock hit an intraday high of Rs. 2215.00 and intraday low of 2160.60. The net turnover during the day was Rs. 100137963.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 LacosamideInjection